These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26989807)

  • 21. Odanacatib for the treatment of osteoporosis.
    Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
    Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of romosozumab and its potential in the management of osteoporosis.
    Lim SY; Bolster MB
    Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.
    Papapoulos SE
    Nat Rev Endocrinol; 2015 Feb; 11(2):69-70. PubMed ID: 25488486
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacologic treatment of osteoporosis--2011].
    Lakatos P
    Orv Hetil; 2011 Aug; 152(33):1320-6. PubMed ID: 21824859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Status of drug development for the prevention and treatment of osteoporosis.
    Schwarz P; Jørgensen NR; Abrahamsen B
    Expert Opin Drug Discov; 2014 Mar; 9(3):245-53. PubMed ID: 24490672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological agents and natural compounds: available treatments for osteoporosis.
    Martiniakova M; Babikova M; Omelka R
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.
    Vestergaard P; Jorgensen NR; Mosekilde L; Schwarz P
    Osteoporos Int; 2007 Jan; 18(1):45-57. PubMed ID: 16951908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
    McCarroll K; Fitzpatrick D; Lannon R
    Osteoporos Int; 2024 Oct; 35(10):1869-1870. PubMed ID: 39120626
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of osteoporosis treatment on bone mass.
    Appelman-Dijkstra NM; Oei HLDW; Vlug AG; Winter EM
    Best Pract Res Clin Endocrinol Metab; 2022 Mar; 36(2):101623. PubMed ID: 35219602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
    Schultz TC; Valenzano JP; Verzella JL; Umland EM
    Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romosozumab in the treatment of osteoporosis.
    Kobza AO; Papaioannou A; Lau AN; Adachi JD
    Immunotherapy; 2020 Sep; 12(13):965-981. PubMed ID: 32752907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Romosozumab : a new treatment for severe osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romosozumab: First Global Approval.
    Markham A
    Drugs; 2019 Mar; 79(4):471-476. PubMed ID: 30805895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.